Similar companies
Income Statement (USD)
Q2 '24 | QoQ | |
---|---|---|
Revenue | 150M | 8.6% |
Gross Profit | 116M | 10.4% |
Cost of Revenue | 35M | 2.9% |
Operating expense | 149M | 2% |
Net Income | -33M | 13.9% |
EBITDA | -27M | 21.9% |
Balance Sheet (USD)
Q2 '24 | QoQ | |
---|---|---|
Total Assets | 1.21B | 8.1% |
Total Liabilities | 850M | 11.6% |
Total Equity | 362M | 0.7% |
Shares Outstanding | 108M | 0.4% |
Cash Flow (USD)
Q2 '24 | QoQ | |
---|---|---|
Cash from operations | -1.7M | 94.6% |
Cash from investing | -374M | 252.1% |
Cash from financing | 87M | 40893.9% |
EPS
Financial Highlights for NovoCure in Q2 '24
NovoCure reported a revenue of 150M, which is a 8.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 116M, marking a 10.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 35M, a 2.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 149M, showing a 2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -33M, showing a 13.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -27M, showing a 21.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for NovoCure with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.